Nicolas Hug reveals how UCB´s new facility in Bulle, Switzerland, is one of the largest microbial derived pharmaceuticals plants in Europe; how the key challenge for manufacturers today is to guarantee supplies by building a robust network; and why manufacturing is where dreams become reality, taking the results from a clinical trial and turning them in to something tangible.
UCB’s 300 million CHF investment, the largest biotech project seen in Europe in recent years, has recently become fully operational. To what extent has this facility been a game changer for the Group?
"Our aspiration is to become the biopharmaceutical, patient-centred, company of choice internationally."
